megestrol / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 138 Diseases   26 Trials   26 Trials   791 News 


«12345678910»
  • ||||||||||  Lynparza (olaparib) / Merck (MSD), AstraZeneca
    BRCA2 Mutated Recurrent Adult Granulosa Cell Tumor Treated with PARP Inhibitor (Exhibition / Poster Area) -  Oct 9, 2022 - Abstract #ESMOAsia2022ESMO_Asia_964;    
    Unlike epithelial ovarian cancer (EOC) BRCA mutations have not been reported in aGCT. In our patient, multiple platinum-sensitive recurrences similar to EOC and subsequent finding of BRCA2 mutation makes a case for further investigation of such aberrations in aGCT with possible therapeutic implications.
  • ||||||||||  megestrol / Generic mfg.
    Review:  Oncological outcomes in fertility-sparing treatment in stage IA-G2 endometrial cancer. (Pubmed Central) -  Oct 4, 2022   
    A total of 103 patients were included and treated with a combination of LNG-IUD plus megestrol acetate (MA) or medroxyprogesterone acetate (MPA), gonadotrophin-releasing hormone (GnRH) plus MPA/MA, hysteroscopic resectoscope (HR), and dilation and curettage (D&C)...It can be employed for patients with early-stage diseases motivated to maintain reproductive function. Indeed, the results are encouraging, but the sample size must be increased.
  • ||||||||||  megestrol / Generic mfg.
    Review, Journal:  Appetite stimulants for people with cystic fibrosis. (Pubmed Central) -  Sep 30, 2022   
    We included four trials (70 participants) comparing appetite stimulants (cyproheptadine hydrochloride and megestrol acetate) to placebo; the numbers of adults or children within each trial were not always reported...Future trials of appetite stimulants should use a validated measure of symptoms including a disease-specific instrument for measuring poor appetite. This review highlights the need for multicentred, adequately powered, and well-designed trials to evaluate agents to safely increase appetite in people with cystic fibrosis and to establish the optimal mode of treatment.
  • ||||||||||  megestrol / Generic mfg., mirtazapine / Generic mfg., dronabinol oral / Generic mfg.
    Evaluation of the Use of Appetite Stimulants in Pediatric Patients with Cystic Fibrosis (Exhibit Hall- RFPT A) -  Sep 13, 2022 - Abstract #NACFC2022NACFC_693;    
    Weight z-scorecontinued to trend up from 3 to 6 months and plateaued from 6 to 12months. Cyproheptadine was associated with improvement in pulmonaryfunction in the first 3 months of therapy, which supports the relationshipbetween weight gain and better pulmonary function in people with CF.These findings suggest that appetite stimulants contribute to weight gainin children with CF, particularly within the first 3 months of therapy.
  • ||||||||||  megestrol / Generic mfg.
    When Endometrial Cancer Spares No Age (ePoster kiosks (Exhibition area)) -  Sep 12, 2022 - Abstract #ESGO2022ESGO_1048;    
    More studies are needed to predict the response to HT by investigating the molecular classification of endometrial cancer. A consensus on a fertility sparing treatment should be made for young patients with EC.
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca, Lynparza (olaparib) / Merck (MSD), AstraZeneca
    Trial initiation date:  RAINBO: Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (clinicaltrials.gov) -  Sep 7, 2022   
    P2/3,  N=1611, Recruiting, 
    The clinical relevance of their detection is not demonstrated. Initiation date: Jun 2022 --> Nov 2021
  • ||||||||||  prednisone / Generic mfg., abiraterone acetate / Generic mfg., megestrol / Generic mfg.
    To Be Colorectal or Not to Be? That Is the Question (Crown Ballroom) -  Sep 4, 2022 - Abstract #ACG2022ACG_3037;    
    Prostate cancer can invade the rectum through lymphatic involvement, through direct invasion, or rarely through seeding status post needle biopsy. Although rare, it is crucial to consider prostatic rectal metastases when seeing patients with new-onset gastrointestinal symptoms (e.g. obstruction or bleeding) and a history of advanced prostate cancer.
  • ||||||||||  megestrol / Generic mfg., rosuvastatin / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date:  Megestrol Acetate Plus Rosuvastatin in Young Women With Atypical Endometrial Hyperplasia (clinicaltrials.gov) -  Aug 29, 2022   
    P2/3,  N=36, Completed, 
    Moreover, in patients using this management method, pregnancy could be achieved using reproductive techniques. Recruiting --> Completed | Trial completion date: Aug 2023 --> Jun 2022 | Trial primary completion date: Aug 2023 --> Jun 2022
  • ||||||||||  megestrol / Generic mfg.
    Journal:  Fertility-Sparing Management May Be Considered in Young Women with Uterine Sarcoma. (Pubmed Central) -  Aug 27, 2022   
    Six patients received adjuvant treatment: megestrol (n = 5) and chemotherapy (n = 1)...Fertility-sparing management may be considered in some patients with uterine sarcoma; however, it may not be appropriate in high-grade endometrial stromal sarcoma. Patients with adenosarcoma may have a low chance of childbearing.
  • ||||||||||  megestrol / Generic mfg.
    Clinical, Review, Journal:  Uterine sparing management in patients with endometrial cancer: a narrative literature review. (Pubmed Central) -  Aug 24, 2022   
    Evaluations at three and six months could be performed by office endometrial biopsy and/or hysteroscopic directed biopsy especially in the presence of levonorgestrel intrauterine system, and in cases of remission, either a pregnancy attempt or maintenance therapy should be considered. After childbearing, hysterectomy with bilateral salpingo-oophorectomy is recommended, whereas ovarian preservation could be considered depending on the patient's age and whether they fulfil the strict criteria selection.
  • ||||||||||  megestrol / Generic mfg.
    Trial primary completion date, Head-to-Head:  Levonorgestrel-Releasing Intrauterine System (LNG-IUS) in the Management of Atypical Endometrial Hyperplasia (clinicaltrials.gov) -  Aug 8, 2022   
    P3,  N=40, Recruiting, 
    After childbearing, hysterectomy with bilateral salpingo-oophorectomy is recommended, whereas ovarian preservation could be considered depending on the patient's age and whether they fulfil the strict criteria selection. Trial primary completion date: Dec 2022 --> Apr 2023
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca, Lynparza (olaparib) / Merck (MSD), AstraZeneca
    Enrollment open:  RAINBO: Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (clinicaltrials.gov) -  Jul 14, 2022   
    P2/3,  N=1611, Recruiting, 
    Potential drugs targeting this gene signature deserve further attention in the treatment of HCC. Not yet recruiting --> Recruiting
  • ||||||||||  megestrol / Generic mfg.
    Retrospective data, Journal:  Efficacy and Safety of Megestrol in the Hospitalized Older Person. (Pubmed Central) -  Jul 3, 2022   
    Conclusion In older hospitalized patients, megestrol did not increase weight, and did not improve albumin. No thromboembolic events were observed, but this may be because of a limited duration of observation of therapy and the routine use of anticoagulation prophylaxis in the inpatient setting.
  • ||||||||||  megestrol / Generic mfg.
    Trial completion date, Trial primary completion date, IO biomarker:  Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy (clinicaltrials.gov) -  Jun 16, 2022   
    P2,  N=28, Recruiting, 
    Diagnostic follow-up with hysteroscopy was associated with a higher pregnancy rate, although this requires confirmation in adequately powered randomized trials. Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
  • ||||||||||  Virexxa (sodium cridanimod) / Xenetic Biosci
    Enrollment change, Trial termination:  An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer (clinicaltrials.gov) -  Jun 7, 2022   
    P2,  N=25, Terminated, 
    Future research should carefully consider biological mechanisms to guide more nuanced selection of endpoints and interventions, including product, dose and administration. N=36 --> 25 | Completed --> Terminated; The study was discontinued due to a change in development strategy and not due safety concern.
  • ||||||||||  Cesamet (nabilone) / Bausch Health, Viatris
    Journal:  Efficacy of cannabis and its constituents in disease management: Insights from clinical studies. (Pubmed Central) -  May 29, 2022   
    The cannabis constituents have also been used in combination with other agents such as megestrol acetate in some clinical trials...This article provides a compilation of published studies focusing on clinal trials on the therapeutic effects of cannabis. The adverse effects of cannabis and its constituents are also discussed.
  • ||||||||||  megestrol / Generic mfg.
    Trial initiation date, Trial primary completion date, Head-to-Head:  Levonorgestrel-Releasing Intrauterine System (LNG-IUS) in the Management of Atypical Endometrial Hyperplasia (clinicaltrials.gov) -  May 13, 2022   
    P3,  N=40, Recruiting, 
    In this study, alternative oral NEs of low-solubility drug MGA were developed considering the above features. Trial primary completion date: Sep 2022 --> Dec 2022 | Initiation date: Apr 2022 --> Jul 2022
  • ||||||||||  metformin / Generic mfg., megestrol / Generic mfg.
    Review, Journal:  Endometrial Cancer Management in Young Women. (Pubmed Central) -  Apr 24, 2022   
    The use of metformin may increase the effectiveness of such treatment...In addition to pharmacological treatment, hysteroscopic resection may be used-part of the uterine muscle adjacent to the pathologically changed endometrium may also undergo resection. An alternative is the administration of estrogen receptor modulators (e.g., SERMs) or aromatase inhibitors, or GnRH agonists.